Management of Hyperparathyroidism

Introduction to Hyperparathyroidism

The management of elevated parathyroid hormone levels should be tailored to the specific type of hyperparathyroidism and underlying etiology, with treatment options ranging from medical therapy to surgical intervention depending on disease severity 1, 2

Secondary hyperparathyroidism is characterized by normal or low serum calcium with elevated parathyroid hormone (PTH), commonly seen in chronic kidney disease (CKD), vitamin D deficiency, and malabsorption syndromes 2
Secondary hyperparathyroidism results from reduced plasma levels of 1,25(OH)2D leading to decreased intestinal calcium absorption and impaired suppression of PTH synthesis 1

First-line interventions for CKD-related secondary hyperparathyroidism include controlling serum phosphorus through dietary phosphorus restriction and phosphate binders, targeting serum phosphorus within the normal range, and ensuring adequate vitamin D status 1, 3
Vitamin D therapy, including active vitamin D analogs such as calcitriol, paricalcitol, or doxercalciferol, should be initiated for patients with CKD-related secondary hyperparathyroidism 1, 3
The American Journal of Kidney Diseases recommends adjusting the dosage of vitamin D analogs according to the severity of hyperparathyroidism and monitoring serum calcium and phosphorus every 2 weeks for 1 month after initiating therapy, then monthly 3

Parathyroidectomy should be considered for severe hyperparathyroidism with hypercalcemia that precludes medical therapy, with surgical options including total parathyroidectomy (TPTX), total parathyroidectomy with autotransplantation (TPTX+AT), and subtotal parathyroidectomy (SPTX) 1, 2, 4
TPTX+AT has become the first choice for treatment of secondary hyperparathyroidism in many clinical centers due to lower risk of permanent hypoparathyroidism 4

For patients on medical therapy, the American Journal of Kidney Diseases recommends monitoring serum calcium and phosphorus monthly and measuring intact parathyroid hormone (iPTH) every 1-3 months until target levels are achieved, then every 3 months 3
For post-parathyroidectomy patients, ionized calcium should be monitored every 4-6 hours for the first 48-72 hours, and calcium supplementation should be provided if hypocalcemia develops 1, 2

For patients with X-linked hypophosphatemia and secondary hyperparathyroidism, cinacalcet may be considered with close monitoring, though it is not licensed for this indication 5, 6
Parathyroidectomy should be considered in patients with tertiary hypercalcemic hyperparathyroidism 5, 6